Sue Langham1, Antony Wright1, James Kenworthy2, Richard Grieve3, William C N Dunlop4. 1. Maverex Ltd., Manchester, UK. 2. Mundipharma International Ltd., Cambridge, UK. Electronic address: james.kenworthy@mundipharma.com. 3. London School of Hygiene and Tropical Medicine, London, UK. 4. Mundipharma International Ltd., Cambridge, UK.
Abstract
BACKGROUND: Heroin overdose is a major cause of premature death. Naloxone is an opioid antagonist that is effective for the reversal of heroin overdose in emergency situations and can be used by nonmedical responders. OBJECTIVE: Our aim was to assess the cost-effectiveness of distributing naloxone to adults at risk of heroin overdose for use by nonmedical responders compared with no naloxone distribution in a European healthcare setting (United Kingdom). METHODS: A Markov model with an integrated decision tree was developed based on an existing model, using UK data where available. We evaluated an intramuscular naloxone distribution reaching 30% of heroin users. Costs and effects were evaluated over a lifetime and discounted at 3.5%. The results were assessed using deterministic and probabilistic sensitivity analyses. RESULTS: The model estimated that distribution of intramuscular naloxone, would decrease overdose deaths by around 6.6%. In a population of 200,000 heroin users this equates to the prevention of 2,500 premature deaths at an incremental cost per quality-adjusted life year (QALY) gained of £899. The sensitivity analyses confirmed the robustness of the results. CONCLUSIONS: Our evaluation suggests that the distribution of take-home naloxone decreased overdose deaths by around 6.6% and was cost-effective with an incremental cost per QALY gained well below a £20,000 willingness-to-pay threshold set by UK decision-makers. The model code has been made available to aid future research. Further study is warranted on the impact of different formulations of naloxone on cost-effectiveness and the impact take-home naloxone has on the wider society.
BACKGROUND:Heroinoverdose is a major cause of premature death. Naloxone is an opioid antagonist that is effective for the reversal of heroinoverdose in emergency situations and can be used by nonmedical responders. OBJECTIVE: Our aim was to assess the cost-effectiveness of distributing naloxone to adults at risk of heroinoverdose for use by nonmedical responders compared with no naloxone distribution in a European healthcare setting (United Kingdom). METHODS: A Markov model with an integrated decision tree was developed based on an existing model, using UK data where available. We evaluated an intramuscular naloxone distribution reaching 30% of heroin users. Costs and effects were evaluated over a lifetime and discounted at 3.5%. The results were assessed using deterministic and probabilistic sensitivity analyses. RESULTS: The model estimated that distribution of intramuscular naloxone, would decrease overdose deaths by around 6.6%. In a population of 200,000 heroin users this equates to the prevention of 2,500 premature deaths at an incremental cost per quality-adjusted life year (QALY) gained of £899. The sensitivity analyses confirmed the robustness of the results. CONCLUSIONS: Our evaluation suggests that the distribution of take-home naloxone decreased overdose deaths by around 6.6% and was cost-effective with an incremental cost per QALY gained well below a £20,000 willingness-to-pay threshold set by UK decision-makers. The model code has been made available to aid future research. Further study is warranted on the impact of different formulations of naloxone on cost-effectiveness and the impact take-home naloxone has on the wider society.
Authors: Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni Journal: J Pharmacol Exp Ther Date: 2018-11-08 Impact factor: 4.030
Authors: Joanne Neale; Caral Brown; Aimee N C Campbell; Jermaine D Jones; Verena E Metz; John Strang; Sandra D Comer Journal: Addiction Date: 2018-12-28 Impact factor: 6.526
Authors: Magdalena Cerdá; Mohammad S Jalali; Ava D Hamilton; Catherine DiGennaro; Ayaz Hyder; Julian Santaella-Tenorio; Navdep Kaur; Christina Wang; Katherine M Keyes Journal: Epidemiol Rev Date: 2022-01-14 Impact factor: 6.222
Authors: Joanne Neale; Nicola J Kalk; Stephen Parkin; Caral Brown; Laura Brandt; Aimee N C Campbell; Felipe Castillo; Jermaine D Jones; John Strang; Sandra D Comer Journal: J Subst Abuse Treat Date: 2020-08-05
Authors: Elizabeth Beaulieu; Catherine DiGennaro; Erin Stringfellow; Ava Connolly; Ava Hamilton; Ayaz Hyder; Magdalena Cerdá; Katherine M Keyes; Mohammad S Jalali Journal: Value Health Date: 2020-10-26 Impact factor: 5.725
Authors: Jamie Weinand; Athena Huckaby; Olivia Chavez; Ramona Sharma; Jeanette Lara; Laura Leija; Christopher Morriss; Shawn Rowland; Davena Norris; Minerva Medrano de Ramirez; Salvador Adame-Zambrano; John Andazola; Ivan De La Rosa Journal: PRiMER Date: 2019-09-13